Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glial Cells01:04

Glial Cells

Overview
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current-Driven Symmetry Breaking and Spin-Orbit Polarization in Chiral Wires.

ACS nano·2026
Same author

Management of glaucoma as a neurodegenerative disease.

Neurodegenerative disease management·2026
Same author

Correction: Yap et al. Real-Time Imaging of Retinal Ganglion Cell Apoptosis. <i>Cells</i> 2018, <i>7,</i> 60.

Cells·2025
Same author

Prospective randomized control trial measuring posterior capsular opacification rates and visual outcomes following insertion of two monofocal intraocular lenses: the hydrophobic RayOne 800C and the hydrophilic RayOne 600C: 12-month results.

Journal of cataract and refractive surgery·2025
Same author

Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study.

The British journal of ophthalmology·2025
Same author

The Effects of the COVID-19 Pandemic on the Follow-Up of Patients with Age-Related Macular Degeneration in a Tertiary Hospital in London, the UK.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Jun 4, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

19.4K

Review: Neuroprotective Nanocarriers in Glaucoma.

Kun Pei1, Maria Georgi2,3, Daniel Hill1

  • 1UCL Institute of Ophthalmology, London EC1V 9EL, UK.

Pharmaceuticals (Basel, Switzerland)
|September 28, 2024
PubMed
Summary

Nanotechnology offers a promising solution for glaucoma treatment by improving drug delivery to protect retinal ganglion cells (RGCs) and prevent vision loss. This approach overcomes limitations of traditional methods, enhancing therapeutic efficacy for irreversible blindness.

Keywords:
glaucomananocarriersnanomedicineneuroprotectionneuroprotectiveocular neurodegenerative diseaseretinal ganglion cell

More Related Videos

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

722
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

129

Related Experiment Videos

Last Updated: Jun 4, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

19.4K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

722
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

129

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Materials Science

Background:

  • Glaucoma is a leading cause of irreversible blindness, characterized by retinal ganglion cell (RGC) loss.
  • Current treatments targeting intraocular pressure (IOP) are insufficient for many patients, necessitating new therapeutic strategies.
  • Effective drug delivery to the eye is hindered by physiological barriers, limiting treatment efficacy.

Purpose of the Study:

  • To review current nanotechnology-based approaches for glaucoma treatment.
  • To explore the use of nanocarriers for delivering neuroprotective drugs to RGCs.
  • To assess the potential of these advanced delivery systems in preventing RGC death and optic nerve degeneration.

Main Methods:

  • Review of scientific literature on nanotechnology applications in glaucoma therapy.
  • Analysis of studies combining neuroprotective agents with various nanocarrier systems.
  • Evaluation of drug bioavailability and therapeutic outcomes in preclinical and clinical settings.

Main Results:

  • Nanocarrier systems demonstrate enhanced penetration of ocular barriers, improving drug delivery to target tissues.
  • Combination of neuroprotective drugs with nanocarriers shows potential in preventing RGC apoptosis and preserving optic nerve function.
  • Non-invasive nanodelivery methods offer an alternative to invasive intravitreal injections, potentially reducing side effects.

Conclusions:

  • Nanotechnology holds significant promise for developing novel, effective glaucoma treatments.
  • Targeted delivery of neuroprotective agents via nanocarriers can mitigate RGC loss and slow disease progression.
  • Further research into nanocarrier-based therapies is crucial for advancing glaucoma management and preventing blindness.